INA01, a monoclonal antibody to treat advanced cancers

Cancer is the first cause of mortality in human

Cancer affects 12 million new people in the world every year leading to 8 million deaths each year (World Health Report 2008). Born from biomedical research, the monoclonal antibody INA01 is a treatment for advanced cancers without therapeutic alternative.

INA01, a monoclonal antibody for a targeted anti-cancerous therapy

Initially, INA01 is developed in orphan diseases such as leukemia or lymphoma, and then in more frequent cancers

INA01, an innovative and targeted action on cancer cells

INA01 asphyxiates cancer cells by depriving them of the main fuel, Iron while sparing healthy cells.

Iron, an essential fuel to cells' life

An ordinary cell needs a low amount of ironIron is carried in the blood thanks to a protein, transferrin. Transferrin and its iron bind themselves onto a receiver at the surface of the cell (CD71 receiver). An ordinary cell has a low density of CD71 receiver on its surface.

Cancerous cells' increased iron needs

A cancerous cell has a very active cellular metabolism and needs more iron to breath and replicate itself. The cancerous cell thus strongly expresses the receiver to transferrin (CD71) at the surface of its membrane, allowing an absorbtion of iron suited to its needs. Well fed in iron, the cancerous cell ensures its breathing and cellular proliferation.

The selective action of INA01 on cancerous cells' transferrin receivers

The IN01 monoclonal antybody preferrentially binds itself onto the many cancerous cells’ transferrin receivers (CD71). INA01 prevents the fixing of transferrin on its receiver. Therefore, INA01 blocks the entry of iron into the cell. This iron deficiency leads to the asphyxiation of the cancerous cell and its death by apoptosis (cellular suicide).

INA01 spares healthy cells

Healthy cells’ iron needs are low. They have few transferrin receivers (CD71). In this state of low density of receivers, transferrin has a stronger affinity than antibody INA01INA01 does thus not bind itself onto healthy cells’ receivers which keep an iron consommation that is suited to their cellular activity.

A promising anticancerous treatment

By acting on the cancerous cell’s metabolism, Inatherys goes one step closer to treating advanced cancers without therapeutic alternative.